News & Events



BD Biosciences Announces 2007 Research Grant Program


Applications Now Accepted for Grants Valued at $100,000

Contact: Jeff Ezell
BD Public Relations
(201) 847-5533
Email: jeff_ezell@bd.com

San Diego, CA (June 28, 2007) --

BD Biosciences, a segment of BD (Becton, Dickinson and Company), announced today it is now accepting applications from researchers for grants valued at $100,000. The second annual BD Biosciences Research Grant Program will award BD reagents to applicants who are judged to have presented the most innovative proposals for using BD reagents in their research.

“We understand the great need for and difficulty in obtaining funding in the research community,” said Bill Rhodes, President of BD Biosciences, Cell Analysis. “Our Research Grant Program helps give selected researchers the means to conduct promising projects and reflects BD's ongoing commitment to research and development.”

An independent scientific review panel will select four winners who will each receive $25,000 worth of BD Biosciences research reagents.  Interested applicants should submit abstracts within the preferred fields of cell signaling, stem cell research, immune function or cancer research, but proposals for research in other fields will also be accepted.

Interested researchers should apply online at www.bdbiosciences.com/grant.The application deadline is September 28, 2007, with the selected grant awardees to be announced November 16, 2007.  The 2007 BD Biosciences Research Grant Program is for U.S. residents only.  Terms and conditions apply.

In 2006, BD Biosciences awarded three grants totaling $100,000 to researchers conducting innovative immunology research projects using its research reagents.  More than 200 researchers submitted abstracts for consideration.

About BD

BD, a leading global medical technology company that manufactures and sells medical devices, instruments and reagents, is dedicated to improving people’s health throughout the world. BD is focused on improving drug therapy, enhancing the quality and speed of diagnosing infectious diseases, and advancing research and discovery of new drugs and vaccines. The Company’s capabilities are instrumental in combating many of the world’s most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 27,000 people in approximately 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, industry and the general public. For more information, please visit, www.bd.com.

 

Unless otherwise noted, BD, BD logo and all other trademarks are property of Becton Dickinson and Company. © 2013 BD